Author

Qianhui Zhang

City University of New YorkORCID 0000-0001-7536-5897Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Akihiro Hori· 1 shared Chuanwen KaniD· 1 shared Chun Wang· 1 shared Guanbo WangiD· 1 shared Haruaki NoboriiD· 1 shared Hirofumi SawaiD· 1 shared Hiromitsu Shibayama· 1 shared Jun SatoiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Akihiro Hori

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintOct 20, 2025

HLA-DQ2/8 genotype is associated with strain-level gut microbiome divergence and lower serum pantothenate in healthy adults

Chuanwen Kan, Mo Hu, Ning Wang…·Li Zhang

DOI 10.1101/2025.10.20.683361

humanbulk RNA-seq

𝕏 PostBluesky

BiochemistryJournal of Medicinal ChemistryPeer-reviewedJul 5, 2025

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19

Yuto Unoh, Keiichiro Hirai, Shota Uehara…·Yuki Tachibana

This paper describes the discovery of S-892216, a potent SARS-CoV-2 3CLpro inhibitor with antiviral activity against multiple variants and low cross-resistance to existing drugs.

27 citationstop 1%

experimental assaydrug response / drug discovery

𝕏 PostBluesky